EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jason Rhodes

Partner at Atlas Venture


Jason Rhodes is a partner at Atlas Venture and focuses on the creation, development, and business strategy of novel therapeutics companies. He sits on the boards of Atlas portfolio companies Replimune, Bicycle Therapeutics, and several seed-stage companies. Prior to joining Atlas, Jason was president and CFO of Epizyme (NASDAQ: EPZM), which he joined when it was a private, research-stage company and helped lead through a series of successful partnerships and an IPO in 2013. Prior to that Jason was vice president of business development at Alnylam (NASDAQ: ALNY), and he was a founder and partner with Fidelity Biosciences before that. Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the investment advisory board of the Blavatnik fund at Yale, the advisory board of the BIDMC Institute for RNA Medicine, the industry advisory board of the Models to Medicine (M2M) Center at UMass Amherst, and the Berklee College of Music Presidential Advisory Council.